Previous Chapter Chapter 24: Novel Strategies in Oncology Clinical Trials: The Use of Biological and Imaging Biomarkers Next Chapter

By: Decision Resources Inc

In: The SAGE Handbook of Healthcare

Chapter 24: Novel Strategies in Oncology Clinical Trials: The Use of Biological and Imaging Biomarkers

  • Citations
  • Add to My List
  • Text Size

Novel Strategies in Oncology Clinical Trials: The Use of Biological and Imaging Biomarkers
Novel strategies in oncology clinical trials: The use of biological and imaging biomarkers
Improving Cancer Therapies: Going beyond Survival

The gold standard for evaluating an oncology drug candidate's effectiveness is survival. However, the emergence of biotherapeutics for use in oncology has shifted attention to intermediate indicators of progress in patient-treatment evaluations. By evaluating immunological responses to biotherapeutics, insight may be gained into potential therapeutic improvements to optimize dosage, delivery, and combinations with other therapeutics. Evaluation of the immune response requires quantifying the biological changes, or creating “biomarkers,” that can be related to clinical outcomes. As we discuss, both biological biomarkers and imaging biomarkers are emerging to fill this role.

The development and application of these ...

Looks like you do not have access to this content.

Login

Don’t know how to login?

Click here for free trial login.

Back to Top

Copy and paste the following HTML into your website